Reviewing transcriptional data from a human database, they reported an increase in TBX3 expression in early MASLD followed by a decline as the disease progresses; they found a similar biphasic change in mouse liver in response to a 36-week WD. The gene discussed is TBX3; the disease is metabolic dysfunction-associated steatotic liver disease.